- Home
- LCTX vs FLL Comparison
LCTX vs FLL Comparison
Compare LCTX & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LCTX | FLL |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.9M | 108.7M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | LCTX | FLL |
|---|---|---|
| Price | $1.71 | $3.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.25 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.3M | 141.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,816,000.00 | ★ $299,916,000.00 |
| Revenue This Year | $5.24 | $4.94 |
| Revenue Next Year | $126.78 | $7.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.05 | 7.45 |
| 52 Week Low | $0.37 | $2.25 |
| 52 Week High | $2.09 | $5.59 |
Technical Indicators
Market Signals| Indicator | LCTX | FLL |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 66.94 |
| Support Level | $1.69 | $2.61 |
| Resistance Level | $1.79 | $2.89 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 47.92 | 91.30 |
Price Performance
Historical ComparisonAbout LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.